In parallel with our Phase 1b clinical trial in metastatic breast cancer, which is now closed for recruitment (see “METASTATIC BREAST CANCER TRIAL” section), both healthy volunteers as well as patients with metastatic breast cancer are also invited to participate in a study to develop a blood test that detects both circulating tumor cells as well as cancer stem cells.
This blood test is a key diagnostic component of the overall study.
TITLE OF STUDY – A biomarker study to develop a multicomponent diagnostic screen for the detection of circulating tumor cells (CTC) and cancer stem cells (CSC) using peripheral blood.
You are invited to participate in a research study of a new diagnostic test to detect cancer stem cells in peripheral blood being conducted by the Department of Medical Oncology at The Canberra Hospital, Garran, ACT. The Principal Investigator (PI) for the study is Professor Desmond Yip.
A total of 25 healthy female donors as well as women with metastatic breast cancer will be enrolled if they satisfy the eligibility criteria;
- Age > 18 years of age
- Able and willing to provide written informed consent.
While you are taking part in this study, 23 ml of blood from 10 healthy individuals and 33ml from patients with metastatic breast cancer would be required at 3 different time points (3 weeks apart).
Separately 48ml of blood will be collected from another 5 healthy volunteers.
If you would like more information about participating, please contact:
Emily Baxter at (02) 5124 4102 or email@example.com
Interested in learning more? Enter your details below.
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founder & Director at EpiAxis Therapeutics